OverviewSuggest Edit

Inivata is a clinical cancer genomics company focused on harnessing the potential of circulating tumour DNA (ctDNA) analysis to improve cancer testing and treatment. The Company offers a tagged-amplicon sequencing method, that allows amplification and deep sequencing of genomic regions spanning thousands of bases from individual copies of fragmented DNA.

TypePrivate
Founded2014
HQGreat Abington, GB
Websiteinivata.com

Latest Updates

Employees (est.) (Jan 2020)77(-4%)
Revenue (FY, 2018)£128.2 K(+233%)

Key People/Management at Inivata

Jeff Buchalter

Jeff Buchalter

Non-Executive Chairman
Clive Morris

Clive Morris

Chief Executive
Robert Tansley

Robert Tansley

Non-Executive Director
Craig Richardson

Craig Richardson

Non-Executive Director
Nitzan Rosenfeld

Nitzan Rosenfeld

Chief Scientific Officer
Jeanne Bolger

Jeanne Bolger

Non-Executive Director
Show more

Inivata Office Locations

Inivata has offices in Great Abington and Morrisville
Great Abington, GB (HQ)
Granta Park
Morrisville, US
7020 Kit Creek Rd #140
Show all (2)

Inivata Financials and Metrics

Summary Metrics

Founding Date

2014

Inivata total Funding

$104.4 m

Inivata latest funding size

$52.60 m

Time since last funding

10 months ago

Inivata investors

Inivata's latest funding round in March 2019 was reported to be $52.6 m. In total, Inivata has raised $104.4 m
Show all financial metrics

Inivata Revenue

Embed Graph
View revenue for all periods
Inivata's revenue was reported to be £128.19 k in FY, 2018
GBP

Revenue (FY, 2018)

128.2k

Gross profit (FY, 2018)

31.2k

Gross profit margin (FY, 2018), %

24.3%

Net income (FY, 2018)

(16.7m)

EBIT (FY, 2018)

(19.8m)

Cash (31-Dec-2018)

6.9m
GBPFY, 2017FY, 2018

Revenue

38.5k128.2k

Cost of goods sold

15.5k97.0k

Gross profit

23.0k31.2k

Gross profit Margin, %

60%24%
GBPFY, 2016FY, 2017FY, 2018

Cash

1.0m5.9m6.9m

Accounts Receivable

57.0k22.7k

Current Assets

3.4m8.7m10.1m
GBPY, 2018

Financial Leverage

1.2 x
Show all financial metrics

Inivata Online and Social Media Presence

Embed Graph

Inivata Blogs

Pioneering and Focused on Making a Difference to Cancer Management

Liquid biopsy offers the potential to transform the way physicians manage cancer and deliver significant benefits to patients by guiding and personalizing treatment, monitoring response and detecting relapse. The post Pioneering and Focused on Making a Difference to Cancer Management appeared first…

Inivata and the European Organisation for Research and Treatment of Cancer (EORTC) collaborate in Phase II NSCLC study

The post Inivata and the European Organisation for Research and Treatment of Cancer (EORTC) collaborate in Phase II NSCLC study appeared first on Welcome to Inivata.

A personal passion for innovation and to make a difference to cancer care

The post A personal passion for innovation and to make a difference to cancer care appeared first on Welcome to Inivata.

Novel approach based on InVision® liquid biopsy platform predicts response to immune checkpoint inhibitors

The post Novel approach based on InVision® liquid biopsy platform predicts response to immune checkpoint inhibitors appeared first on Welcome to Inivata.

Targeted sequencing of plasma cell-free DNA to predict response to PD1 inhibitors in advanced non-small cell lung cancer

Nicolas Guibert, Greg Jones, John F. Beeler, Vincent Plagnol, Clive Morris, Jean Mourlanette, Myriam Delaunay, Laura Keller, Isabelle Rouquette, Gilles Favre, Anne Pradines, Julien Mazieres The post Targeted sequencing of plasma cell-free DNA to predict response to PD1 inhibitors in advanced non-sma…

Inivata to Present New Clinical Data on the Utility of Liquid Biopsy and InVisionFirst®-Lung at World Conference on Lung Cancer 2019

Research Triangle Park, NC, USA and Cambridge, UK, August 29, 2019 — Inivata, a leader in liquid biopsy, is pleased to announce that the Company and its world-leading collaborators will showcase cutting-edge data at the International Association for the Study of Lung Cancer (IASLC) World Conference …
Show more

Inivata Frequently Asked Questions

  • When was Inivata founded?

    Inivata was founded in 2014.

  • Who are Inivata key executives?

    Inivata's key executives are Jeff Buchalter, Clive Morris and Robert Tansley.

  • How many employees does Inivata have?

    Inivata has 77 employees.

  • What is Inivata revenue?

    Latest Inivata annual revenue is £128.2 k.

  • What is Inivata revenue per employee?

    Latest Inivata revenue per employee is £1.7 k.

  • Who are Inivata competitors?

    Competitors of Inivata include Biosignatures, Stratify Genomics and HistoGeneX.

  • Where is Inivata headquarters?

    Inivata headquarters is located at Granta Park, Great Abington.

  • Where are Inivata offices?

    Inivata has offices in Great Abington and Morrisville.

  • How many offices does Inivata have?

    Inivata has 2 offices.